Literature DB >> 17546551

Extracorporeal membrane oxygenation: experience in an adult medical ICU.

G Hermans1, W Meersseman, A Wilmer, B Meyns, H Bobbaers.   

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is a technology that can provide extracorporeal gas exchange to patients with severe pulmonary or cardiac dysfunction. We report on our clinical experience with ECMO in critically ill patients.
METHODS: We performed a retrospective analysis of 23 patients treated with ECMO in a medical intensive care unit in a tertiary referral academic centre.
RESULTS: 13 patients were considered immunocompetent and 10 were immunocompromised when extracorporeal membrane oxygenation was started. 16 patients presented with acute respiratory distress syndrome (ARDS), 2 patients had intractable cardiac failure, and 5 patients had combined respiratory and cardiac failure. In 16 patients, a veno-venous bypass was constructed; in 7 patients, the initial bypass was venoarterial. 11 patients survived. In 2 patients technical complications were fatal.
CONCLUSIONS: Our data indicate that patients with community-acquired pneumonia and no underlying disease will benefit most from this technique. However, long-term survival is possible in immunocompromised patients. Venoarterial bypass can carry a higher risk for technical complications. Increasing experience apparently also reduces the risk of technical complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17546551     DOI: 10.1055/s-2006-955942

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  1 in total

1.  Successful use of extracorporeal membrane oxygenation in a human immunodeficiency virus infected patient with severe acute respiratory distress syndrome.

Authors:  Robertas Samalavicius; Mindaugas Serpytis; Donata Ringaitiene; Daiva Grazulyte; Ruta Bertasiute; Bernardas Rimkus; Raimonda Matulionyte; Ruta Ambrazaitiene; Jurate Sipylaite; Tomas Kacergius; Laimonas Griskevicius
Journal:  AIDS Res Ther       Date:  2014-11-21       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.